|Year : 2015 | Volume
| Issue : 1 | Page : 34-42
Interleukin‑1 gene cluster variants in hemodialysis patients with end stage renal disease: An association and meta‑analysis
G Tripathi1, D Rangaswamy2, M Borkar3, N Prasad2, RK Sharma2, SN Sankhwar4, S Agrawal5
1 Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India; Department of Pathology and Laboratory Medicine, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
2 Department of Nephrology, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
3 Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India; Snyder Institute of Chronic Diseases, Faculty of Medicine, University of Calgary, Calgary, Alberta, Canada
4 Department of Urology, CSSMU, Lucknow, Uttar Pradesh, India
5 Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Lucknow, Uttar Pradesh, India
|Date of Web Publication||12-Jan-2015|
Department of Medical Genetics, Sanjay Gandhi Post Graduate Institute of Medical Sciences, Raebareli Road, Lucknow - 226 014, Uttar Pradesh
Source of Support: Department of Biotechnology and Jawaharlal Nehru Memorial fund, New Delhil, Conflict of Interest: None
We evaluated whether polymorphisms in interleukin (IL-1) gene cluster (IL-1 alpha [IL-1A], IL-1 beta [IL-1B], and IL-1 receptor antagonist [IL-1RN]) are associated with end stage renal disease (ESRD). A total of 258 ESRD patients and 569 ethnicity matched controls were examined for IL-1 gene cluster. These were genotyped for five single-nucleotide gene polymorphisms in the IL-1A, IL-1B and IL-1RN genes and a variable number of tandem repeats (VNTR) in the IL-1RN. The IL-1B − 3953 and IL-1RN + 8006 polymorphism frequencies were significantly different between the two groups. At IL-1B, the T allele of − 3953C/T was increased among ESRD (P = 0.0001). A logistic regression model demonstrated that two repeat (240 base pair [bp]) of the IL-1Ra VNTR polymorphism was associated with ESRD (P = 0.0001). The C/C/C/C/C/1 haplotype was more prevalent in ESRD = 0.007). No linkage disequilibrium (LD) was observed between six loci of IL-1 gene. We further conducted a meta-analysis of existing studies and found that there is a strong association of IL-1 RN VNTR 86 bp repeat polymorphism with susceptibility to ESRD (odds ratio = 2.04, 95% confidence interval = 1.48-2.82; P = 0.000). IL-1B − 5887, +8006 and the IL-1RN VNTR polymorphisms have been implicated as potential risk factors for ESRD. The meta-analysis showed a strong association of IL-1RN 86 bp VNTR polymorphism with susceptibility to ESRD.
Keywords: End stage renal disease, haplotype, interleukin-1 gene cluster, meta-analysis, pro-inflammatory, variable number of tandem repeats
|How to cite this article:|
Tripathi G, Rangaswamy D, Borkar M, Prasad N, Sharma R K, Sankhwar S N, Agrawal S. Interleukin‑1 gene cluster variants in hemodialysis patients with end stage renal disease: An association and meta‑analysis. Indian J Nephrol 2015;25:34-42
|How to cite this URL:|
Tripathi G, Rangaswamy D, Borkar M, Prasad N, Sharma R K, Sankhwar S N, Agrawal S. Interleukin‑1 gene cluster variants in hemodialysis patients with end stage renal disease: An association and meta‑analysis. Indian J Nephrol [serial online] 2015 [cited 2021 May 19];25:34-42. Available from: https://www.indianjnephrol.org/text.asp?2015/25/1/34/135350
| Introduction|| |
Cytokines are small, short-acting glycoprotein's that regulate immune response. Inter-individual differences in cytokine production influence immune and inflammatory responses. Patients with end-stage renal disease (ESRD) have an impaired immune response causing an imbalance of Th1/Th2 cytokine network. Interleukin (IL-1) is involved in the inflammatory response, cell growth, and tissue repair. It has three well-studied members, two agonists, IL-1 alpha (IL-1A) and IL-1 beta (IL-1B), and the IL-1 receptor antagonist (IL-1Ra).  IL-1A and B are proinflammatory cytokines, which bind to the IL-1 receptor, while the Ra, a competitive inhibitor at the receptor site of both molecules, which down-regulates the immune response.  Expression of IL-1Ra depends upon IL-1RN gene, which has a length variation within intron 2 caused by 86 bp variable number of tandem repeats (VNTR).  According to the number of 86 bp repeats, there are five alleles corresponding to allele I (410 bp), II (240 bp), III (500 bp), IV (325 bp) and V (595 bp).  Allele I and II are involved in the production of IL-1Ra. IL-1 gene polymorphisms have been associated with diseases in which inflammation is suspected to play a role. ,, Their localization in regulatory regions suggests that they may modulate IL-1 protein production by directly affecting transcription, leading to their association with altered levels of IL-1.
Polymorphisms of IL genes may influence gene transcription and thereby modulate the risk of progression of renal disease. The observed inconsistencies in the data regarding associations between single-nucleotide gene polymorphisms (SNPs) and their presumed phenotypic expression emphasize the need to recognize conceptual and methodological aspects such as haplotypic rather than single SNP variations and the influence of pathway genes with synergistic or antagonistic effects that ultimately determine the phenotype. 
The goal of this study was to elucidate whether polymorphisms in IL-1 gene cluster (IL-1A, IL-1B, and IL-1RN) are associated with ESRD in north Indians. Both ESRD patients and the controls were genotyped for the IL-1A -889C/T, IL-1B (+3953C/T, -5887C/T, -511C/T), IL-1RN + 8006C/T and IL-1RN 86 bpVNTR gene polymorphisms. We have also carried out a meta-analysis of the existing data.
| Materials and Methods|| |
A total number of 258 unrelated ESRD patients (226, 87.5% males) were included. Inclusion criteria was an estimated glomerular filtration rate (GFR) <15 ml/min/1.73 m 2 . Modification of diet in renal disease formula was used (http://www.radiolopolis.com/index.php/tools/calculators/gfr-calculation-using-mdrd-equation.html) for calculation of GFR. For each patient, the information was collected for various other factors [Supplementary Table 1 [Additional file 1]]. The type of chronic kidney disease was established by history, laboratory investigations, including urine analysis, ultrasound and/or computed tomography scan of the kidneys followed by histopathological evaluation of the renal biopsy specimen if required. Patients were categorized into following subtypes, chronic glomerulonephritis (CGN = 168), chronic interstitial nephritis (CIN = 68), hypertensive nephrosclerosis (HN = 15) and polycystic kidney disease (PKD = 7) group. Patients with diabetic mellitus, receiving corticosteroids, vitamin D or vitamin D derivatives were excluded.
Five hundred and sixty-nine (485 males) age, sex and ethnically matched north Indians from same geographic area were selected as controls. The control subjects were unrelated healthy voluntary blood donors. Subjects with risk factors such as family history of hypertension, diabetes mellitus and hyperlipidemia were excluded. The criterion of defining control sample as normal was based on the absence of any evidence of kidney disease [Supplementary Table 1]. The study was performed in accordance with the ethical standards laid down by the declaration of Helsinki, and all persons involved gave their informed consent prior to the inclusion in the study. The study was approved by the ethical committee of our hospital.
Blood collection, deoxyribonucleic acid extraction and genotyping
Blood samples for measuring the serum biochemical parameters were obtained in the morning after 8 h of fasting. For deoxyribonucleic acid (DNA) extraction, 5.0 ml of venous blood from each study subject was collected in an ethylenediaminetetraacetic acid vial. Genomic DNA was prepared by using QIAmp DNA Blood Mini Kit, Qiagen, Valencia, CA).
Genotyping of the interlukin-1 gene cluster
Genotyping for each marker was conducted in three phase's to rule out the experimental biases. All the samples were coded and double blind. The details of primer and polymerase chain reaction (PCR) condition for studied IL-1 gene are shown in [Supplementary Table 2 [Additional file 2]]. Bi-allelic polymorphisms in the IL-1 gene cluster , were determined by PCR-RFLP analysis.
Statistical analyses for the genotypic and allelic frequencies were performed by Chi-Square test using Graphpad Prism (version 3.0, Graphpad Software, Inc. San Diego, CA USA). Fisher's exact test was used to assess deviation of the genotype frequency from that expected under Hardy-Weinberg Equilibrium (HWE) [Supplementary Table 3 [Additional file 3]]. Power of the study was calculated using Quanto version 1.1 (http://hydra.usc.edu/gxe) with input of following variables, case-control study design, significance level <0.05 (two sided), model of inheritance = log additive, minor allele frequency = 0.15, genetic effect (odds ratio) ≤0.6 or ≥1.6. This study achieved 80% of power, which was sufficient to consider OR of ≤0.6 or ≥1.6, with the type 1 error α =0.05. Bonferroni corrections were applied where ever required. To evaluate the synergistic effect of studied IL-1 gene polymorphisms and risk of ESRD, we performed multivariate analysis using the SPSS software (version 15.0, Biostatistics Consulting University of Massachusetts School of Public Health, US, URL: https://udrive.oit.umass.edu/statdata/spss.zip). Haplotypes were constructed for IL-1 gene through Arlequin software (version 3.1, Computational and Molecular Population Genetics Lab, Institute of Zoology, University of Berne, Baltzerstrasse 6, 3012 Bern, Switzerland, URL: http://cmpg.unibe.ch/software/arlequin3).
The analysis of the linkage disequilibrium (LD) of studied polymorphisms was performed with the use of Haploview v3.11 program; www.broad.mit.edu/mpg/haploview/index.php. This method was used to provide a D prime (D') value. We performed the χ2 test for association of haplotypes, as well as 10,000 permutations, to obtain empirical P values in order to correct for multiple-testing bias. A D' value of zero indicated no LD between different polymorphisms, and D' value of one indicated complete LD. The genotypes of studied group were in HWE for all the six loci.
Search strategy and study selection
0Meta-analyses was conducted for loci IL-1A-889, IL-1B-511and IL-1RN 86 bpVNTR of IL-1 gene based on the PubMed database using the terms "ESRD" or "renal failure" and "IL-1". Study selection criteria were: (1) ESRD patients with creatinine clearance <15 ml/min/1.73 m 2 and were recommended for renal transplantation; (2) controls were drawn from the same geographic area and ethnic background as patients; (3) authors provided original genotype frequencies; and (4) patient and control groups did not overlap between studies. Six case-control studies including present study met the selection criteria. ,,,,
Meta-analyses was conducted for IL-1 gene cluster by fitting random effect models and were checked for small size and publication bias by visually examining the possible asymmetry in funnel plots  and Egger's test. Cochran's Q statistic, to test for heterogeneity and the I2 statistic, to quantify the proportion of the total variation owing to heterogeneity were calculated.  Analyses were carried out using MetaAnalyst Version: Beta 2 (Tufts Medical Center, Boston, MA, USA). 
| Results|| |
Demographic profile and clinical characteristics of patients and controls
The demographic and biochemical profile of both patients and controls is shown in Supplementary [Table 1].
Distribution of genotype and allele frequency of interleukin -1 alpha, interleukin -1 beta and interleukin -1 receptor antagonist
Genotype, allele and carriage allele frequency distributions for IL-1 gene cluster (IL-1A, IL-1B, and IL-1RN) are shown in [Table 1].
|Table 1: Distribution of IL-1 gene polymorphism among patients and controls|
Click here to view
The frequency of C and T allele of IL-1A, the rs1800587 (-889 C/T) in the patient group was 83.1% and 16.9%, respectively. In the control group, it was 86.5% and 13.5% respectively, both groups did not differ significantly (P = 0.0887).
Interlukin-1 beta rs1143627 (−5887C/T) CC genotype frequency was higher in controls (56.6%) than in patients (47.7%; P = 0.0210, OR = 0.69, 95% confidence interval [CI] =0.52-0.94). Allele frequency also differed significantly in both the groups (P = 0.0367). The SNP in IL-1B, the rs1143634 (3953C/T) located in the promoter region of IL-1B was significantly different between the patient and control groups. The T allele frequency at rs1143634 was higher in the patients (36.8%) than in the control subjects (23.9%; P = 0.0001, OR = 1.85, 95% CI = 1.47-2.31). The distribution of rs1143634 (-3953C/T) TT genotype was found to be higher in ESRD patients than in control subjects (P = 0.0027, OR = 2.17, 95% CI = 1.32-3.57).
For IL-1RN, the CC genotype for rs419598 (+8006T/C) was significantly different between ESRD patients and controls (P = 0.0001, OR = 9.35, 95% CI = 2.27-38.58), as well as allele frequencies were significantly different among patients and controls. The two repeats of 86 bp (240 bp) was observed in 32.6% of ESRD and 17.8% in the normal control group. A significant difference was found in the frequency distribution of 2/2 genotypes between both groups (P = 0.0098, OR = 2.31, 95% CI = 1.23-4.32) [Table 1]. The frequency of single repeat (410 bp) in control group was 74.4% and in ESRD it was 61.2% and was found to be a protective allele (P = 0.0001, OR = 0.55, 95% CI = 0.43-0.68) [Table 1].
None of the genotype or allele frequency was statistically different among patient with CGN and CIN. Further, we compared CGN and CIN group with 569 healthy controls and observed significant association (0.001) at allelic and genotypic level of IL-1RN + 8006T/C (rs419598) [Table 2]. IL-1B - 5887 C allele was signifiantly associated for protection (P = 0.041, OR = 0.75). IL-1RN 86 bpVNTR; 1/1 genotype was observed with high frequency in control as compared to CGN (54.8% and 36.3%) (P = 0.0001, OR = 0.47, 95%CI = 0.33-0.67). However 1/2 genotype was significantly associated with the disease phenotype when compared with control and CGN (P = 0.0001, OR = 2.07) and CIN (P = 0.0001, OR = 2.76) group. We have not done any comparison with the sub group HN = 15, PKD = 7 with controls due to the small number of sample size and to avoid false significant P value.
|Table 2: IL-1 genotype and allele frequency distribution among primary kidney disease patients and normal controls|
Click here to view
To demonstrate an independent role of studied IL-1 gene in influencing the risk of ESRD, we assessed the association between IL-1 genotypes and ESRD risk in a multivariate model. In multivariate logistic regression analysis with ESRD patients as the dependent variable and the polymorphisms as independent variables, the IL-1B − 3953C/T polymorphism remained associated with ESRD (Pc = 0.005) [Supplementary Table 4 [Additional file 4]]. In order to assess the cumulative effect of different gene polymorphisms with other risk factors we compared all clinical and demographic parameters of the ESRD patients among two genotypic groups for all the markers studied namely "risk genotype" and "nonrisk genotype" like IL-1B - 5887 TT + CT; as risk and CC; nonrisk genotype. No comparisons were made for IL-1A - 889C/T and IL-1B − 511C/T polymorphism as none of the genotype showed significant association with ESRD [Supplementary Table 4].
Haplotype distribution and linkage disequilibrium
The haplotypes were constructed as shown in [Table 3]. Our study revealed both protective and susceptible haplotypes. We have avoided any calculations for haplotypes which are less frequent than 5%. The haplotype C/C/C/C/C/1 and C/C/C/C/C/2 was observed to be more frequent in patients with high OR (6.53 and 8.71) and significant Pc-value (P = 0.007), which may cause susceptibility to ESRD. Further the haplotype C/C/C/C/T/1 can be considered as an extended protective haplotype as it was found in 31.9% in the controls when compared to 11.6% in ESRD with highly significant P value (P = 0.0007) [Table 3].
|Table 3: Haplotype distribution of IL-1 gene among ESRD patients and control groups (analyzed by Arlequin software v3.1)|
Click here to view
Linkage disequilibrium was investigated for polymorphisms: IL-1A, IL-1B, and IL-1RN located in the promoter and exonic sequence of the IL-1 gene. When we carried out the haplo-view analysis in controls, we identified no LD with D'<1 [Figure 1]a. In patients group there we observed D'<1, which indicates no LD between SNPs [Figure 1]b.
|Figure 1: Linkage disequilibrium map of six loci in interleukin - 1 (IL - 1) alpha, IL-1 beta, and IL-1 receptor antagonist. We estimated the pair wise linkage disequilibrium (LD) by calculating pair wise Dæ and r2. The images were generated with the Haploview software pack. A D' value of θ indicated no LD between different polymorphisms, and D' value of 1 indicated complete LD , (a) Linkage disequilibrium map for six loci of interleukin (IL) - 1 alpha, IL - 1 beta, and IL - 1 receptor antagonist in healthy controls, (b) Linkage disequilibrium map for six loci of interleukin (IL) - 1 alpha, IL - 1 beta, and IL-1 receptor antagonist in end stage renal disease patients|
Click here to view
Estimation of glomerular filtration rate in healthy individuals on the basis of risk and nonrisk genotypes of interlukin -1 gene
An estimation of GFR was computed on the basis of risk and nonrisk genotype of IL-1 gene in healthy controls as described in [Table 4]. We observed that none of the genotype was significantly associated with the risk of lower GFR among healthy controls.
|Table 4: Estimation of GFR in healthy individuals on the basis of risk and nonrisk genotypes of IL-1 gene|
Click here to view
As the results of previous studies ,,,, have been inconsistent, we conducted a meta-analysis for three loci IL-1A - 889C/T, IL-1B - 511C/T and IL-1RN 86 bpVNTR polymorphism with susceptibility to ESRD. The IL-1A - 889C/T polymorphism meta-analysis included seven case-control studies which provided a total of 786 patients and 1079 controls and revealed no association to ESRD (OR = 1.14, 95% CI = 0.78-1.66; P = 0.312) [Figure 2]a. No evidence for heterogeneity was observed between studies (Q = 3.48, P = 0.746 and I2 = 0%). There was no evidence of publication bias from Egger's regression test (P = 0.253). According to IL-1B − 511C/T polymorphism meta-analysis which included seven case-control studies (645 cases vs. 996 controls), there was evidence for heterogeneity between studies as P value was significant (Q = 22.70, P = 0.001 and I2 = 73.6%). We observed no association of this polymorphism with susceptibility to ESRD (OR = 1.38, 95% CI = 0.75-2.54; P = 0.234) [Figure 2]b. The Egger's regression test (P = 0.487) had shown no evidence for publication biasness. The meta-analysis of IL-1RN 86 bpVNTR polymorphism demonstrated a strong association with susceptibility to ESRD (OR = 2.04, 95% CI = 1.48-2.82; P = 0.000) [Figure 2]c. This analysis included 8 association studies providing total number of 754 ESRD patients and 1230 healthy controls. There was no evidence of publication bias, which has been demonstrated by Egger's regression test (0.253). We observed no heterogeneity between the studies (Q = 4.93, P = 0.667 and I2 = 0%).
|Figure 2: Results of a meta - analysis of interleukin (IL) - 1 alpha −889C/T, IL - 1 beta −511C/T and IL - 1 receptor antagonist 86 base pair variable number of tandem repeat gene polymorphism in end stage renal disease and controls, (a) The forest plot of end stage renal disease risk associated with IL - 1 alpha −889C/T polymorphism (TT/CC+CT), (b) The forest plot of end stage renal disease risk associated with IL - 1 beta −511C/T polymorphism (TT/CC+CT), (c) The forest plot of end stage renal disease risk associated with IL - 1 receptor antagonist 86 base pair variable number of tandem repeat polymorphism (2, 2/1, 1 + 1, 2 + others). The squares and horizontal lines correspond to the study - specific odds ratio (OR) and 95% confidence interval (CI). The area of the squares reflects the weight (inverse of the variance). The Diamond represents the summary OR and 95% CI|
Click here to view
| Discussion|| |
Polymorphisms in cytokine genes may be crucial to understand the mechanisms underlying initiation and progression of ESRD. In recent years, several studies have tried to correlate molecular markers for the IL-1 and IL-1 receptor genes with severity or outcome of disease. ,,,,,, ESRD could be considered to be a chronic systemic inﬂammatory state as about 30-50% of dialysis patient's show markedly activated inﬂammatory response. Inflammation is regulated in part by genes of the IL-1 gene cluster. IL-1 stimulates hepatocytes to secrete the acute-phase C-reactive protein. This process brings forward initial damaging stimuli which are not so effective in nature. However, when the initial stimuli cannot be resolved or when anti-inflammatory systems responsible for regulating inflammation are dysfunctional, inflammation persists. A chronic inflammatory state is harmful, rather than protective, as it may result in end organ and vascular damage. 
A silent mutation in the exon 5 of the IL-1B (-5887C/T) gene, which is represented as the minor T allele is associated with the IL-1B high-secretor phenotype,  which can counter act IL-1Ra proinflammatory property. Intron 2 of the IL-1Ra gene includes a region of a variable number of tandem repeats,  carrying 240 bp; two repeats polymorphism, which is related to enhanced production of IL-1Ra. In this study, significant difference was observed between patients and controls. Our results demonstrate that the frequency of allele two (240 bp; 2 repeats) of IL-1Ra in ESRD was ~ 2 times higher than in controls, similar results have been demonstrated by previous studies.  Some studies have suggested that the allelic polymorphism located within intron 2 of IL-1RN differentially modulate IL-1 activity. The IL-1Ra allele two is associated with increased IL-1Ra protein production in vitro.  The C allele of + 8006T/C in exon 2 of IL-1RN is associated with the VNTR allele two (240 bp; two repeats) and is associated with lower expression of IL-1Ra. , In this study, two additional SNP at - 5887C/T BsoFI digested and - 3953C/T TaqI digested have been included as they are present in the promoter region. Interestingly, we observed a positive association of these SNPs with ESRD.
An in vivo study showed that the IL-1A - 889 T allele was associated with increased IL-1A and IL-1B protein levels.  Furthermore, ex vivo analysis of lipopolysaccharide-stimulated peripheral blood mononuclear cells indicated that production of IL-1A from IL-1A with the IL-1A - 889 T allele increased.  IL-1A (-889C/T) allele was not associated with ESRD in our study. Lee et al. has also reported no association of IL-1A - 889 SNP with renal disease.  At the IL-1B - 511C/T position, there was no association with ESRD.
Earlier studies suggested the importance of IL-1 haplotype reflecting differential regulation of IL-1Ra expression by IL-1B and coordinated effects of polymorphisms that regulate IL-1 bioactivity in vivo.  It has been postulated that IL-1Ra genotype and the haplotype of the IL-1Ra and IL-B is important in modulating the susceptibility of certain diseases.  The haplotype C/C/C/C/T/1 of studied IL-1 gene was observed to be associated with protection, so the polymorphisms and haplotypes had an influence on the dynamics of renal disease in patients group. This protective haplotype contains the IL1RN + 8006 'T' allele, which is associated with elevated IL-1RN expression.  An effort to treat rheumatoid arthritis using IL-1Ra was proved to provide promising results in animal models and humans.  Therefore, these studies suggest that altered or imbalanced IL-1 production may affect the risk of developing ESRD.
One major limitation of association studies for multifactorial diseases is low sample size due to inclusion of patients meeting all stringent criterions. Meta-analysis helps to overcome this problem. However, we could take only three loci in IL-1 gene cluster polymorphism for this purpose as only these studies met the criterion as per our study design. Meta-analysis suggests a strong association of the IL-1RN 86 bpVNTR polymorphism with susceptibility to develop ESRD.
| Conclusion|| |
Interlukin-1B -5887, IL-1B -3953, IL-1RN + 8006 and the IL-1RN 86 bpVNTR polymorphisms have been implicated as potential risk factors for ESRD among unrelated ESRD patients. A meta-analysis showed an association of IL-1RN 86 bpVNTR polymorphism with susceptibility to ESRD. Our results implicate the IL-1 gene cluster as an important target of investigation in the development of strategies to slow progression to ESRD and could conceivably provide the basis for defined anti-inflammatory strategies to limit renal disease progression.
| References|| |
Nicklin MJ, Barton JL, Nguyen M, FitzGerald MG, Duff GW, Kornman K. A sequence-based map of the nine genes of the human interleukin-1 cluster. Genomics 2002;79:718-25.
Vandenbroeck K, Goris A. Cytokine gene polymorphisms in multifactorial diseases: Gateways to novel targets for immunotherapy? Trends Pharmacol Sci 2003;24:284-9.
Steinkasserer A, Spurr NK, Cox S, Jeggo P, Sim RB. The human IL-1 receptor antagonist gene (IL1RN) maps to chromosome 2q14-q21, in the region of the IL-1 alpha and IL-1 beta loci. Genomics 1992;13:654-7.
Geismar K, Enevold C, Sørensen LK, Gyntelberg F, Bendtzen K, Sigurd B, et al.
Involvement of interleukin-1 genotypes in the association of coronary heart disease with periodontitis. J Periodontol 2008;79:2322-30.
Sánchez E, Sabio JM, Callejas JL, de Ramón E, Garcia-Portales R, García-Hernández FJ, et al.
Association study of genetic variants of pro-inflammatory chemokine and cytokine genes in systemic lupus erythematosus. BMC Med Genet 2006;7:48.
Arman A, Soylu O, Yildirim A, Furman A, Ercelen N, Aydogan H, et al
. Interleukin-1 receptor antagonist gene VNTR polymorphism is associated with coronary artery disease. Arq Bras Cardiol 2008;91:293-8.
Rao M, Wong C, Kanetsky P, Girndt M, Stenvinkel P, Reilly M, et al.
Cytokine gene polymorphism and progression of renal and cardiovascular diseases. Kidney Int 2007;72:549-56.
Cantagrel A, Navaux F, Loubet-Lescoulié P, Nourhashemi F, Enault G, Abbal M, et al.
Interleukin-1beta, interleukin-1 receptor antagonist, interleukin-4, and interleukin-10 gene polymorphisms: Relationship to occurrence and severity of rheumatoid arthritis. Arthritis Rheum 1999;42:1093-100.
Timms AE, Crane AM, Sims AM, Cordell HJ, Bradbury LA, Abbott A, et al.
The interleukin 1 gene cluster contains a major susceptibility locus for ankylosing spondylitis. Am J Hum Genet 2004;75:587-95.
Borgmann S, Endisch G, Hacker UT, Song BS, Fricke H. Proinflammatory genotype of interleukin-1 and interleukin-1 receptor antagonist is associated with ESRD in proteinase 3-ANCA vasculitis patients. Am J Kidney Dis 2003;41:933-42.
Jin Y, Ruiz P. Molecular genetic analysis of interleukin-1 promoter and receptor antagonist tandem repeat polymorphisms among HLA-identical renal transplant recipient and donor pairs. Transplant Proc 2008;40:1329-32.
Lee SH, Lee TW, Ihm CG, Kim MJ, Woo JT, Chung JH. Genetics of diabetic nephropathy in type 2 DM: Candidate gene analysis for the pathogenic role of inflammation. Nephrology (Carlton) 2005;10 Suppl: S32-6.
Manchanda PK, Bid HK, Kumar A, Mittal RD. Genetic association of interleukin-1beta and receptor antagonist (IL-1Ra) gene polymorphism with allograft function in renal transplant patients. Transpl Immunol 2006;15:289-96.
Wetmore JB, Hung AM, Lovett DH, Sen S, Quershy O, Johansen KL. Interleukin-1 gene cluster polymorphisms predict risk of ESRD. Kidney Int 2005;68:278-84.
Higgins JP, Thompson SG, Deeks JJ, Altman DG. Measuring inconsistency in meta-analyses. BMJ 2003;327:557-60.
Borenstein M, Hedges LV, Higgins JP, Rothstein HR. Introduction to Meta-Analysis. Chichester: Wiley and Sons; 2009. p. 277-92.
Wallace BC, Schmid CH, Lau J, Trikalinos TA. Meta-Analyst: Software for meta-analysis of binary, continuous and diagnostic data. BMC Med Res Methodol 2009 4;9:80.
Settin A, Ismail A, El-Magd MA, El-Baz R, Kazamel A. Gene polymorphisms of TNF-alpha-308 (G/A), IL-10(-1082) (G/A), IL-6(-174) (G/C) and IL-1Ra (VNTR) in Egyptian cases with type 1 diabetes mellitus. Autoimmunity 2009;42:50-5.
Takeda H, Suzuki Y, Takeda Y, Nishise S, Fukui T, Fujishima S, et al.
A multi center study of granulocyte and monocyte adsorption apheresis therapy for ulcerative colitis-clinical efficacy and production of interleukin-1 receptor antagonist. J Clin Apher 2008;23:105-10.
Tazi-Ahnini R, Cox A, McDonagh AJ, Nicklin MJ, di Giovine FS, Timms JM, et al.
Genetic analysis of the interleukin-1 receptor antagonist and its homologue IL-1L1 in alopecia areata: Strong severity association and possible gene interaction. Eur J Immunogenet 2002;29:25-30.
Farrell AM, Dean D, Millard PR, Charnock FM, Wojnarowska F. Cytokine alterations in lichen sclerosus: An immunohistochemical study. Br J Dermatol 2006;155:931-40.
de Jongh CM, Khrenova L, Kezic S, Rustemeyer T, Verberk MM, John SM. Polymorphisms in the interleukin-1 gene influence the stratum corneum interleukin-1 alpha concentration in uninvolved skin of patients with chronic irritant contact dermatitis. Contact Dermatitis 2008;58:263-8.
Lacka K, Paradowska A, Gasinska T, Soszynska J, Wichary H, Kramer L, et al.
Interleukin-1beta gene (IL-1beta) polymorphisms (SNP -511 and SNP+3953) in thyroid-associated ophthalmopathy (TAO) among the Polish population. Curr Eye Res 2009;34:215-20.
Kumar PJ, Clark ML. Kumar and Clark′s Clinical Medicine. 7 th
ed. Edinburgh, UK: Saunders Elsevier; 2009.
Pociot F, Mølvig J, Wogensen L, Worsaae H, Nerup J. A TaqI polymorphism in the human interleukin-1 beta (IL-1 beta) gene correlates with IL-1 beta secretion in vitro
. Eur J Clin Invest 1992;22:396-402.
Freedman BI, Yu H, Spray BJ, Rich SS, Rothschild CB, Bowden DW. Genetic linkage analysis of growth factor loci and end-stage renal disease in African Americans. Kidney Int 1997;51:819-25.
Danis VA, Millington M, Hyland VJ, Grennan D. Cytokine production by normal human monocytes: Inter-subject variation and relationship to an IL-1 receptor antagonist (IL-1Ra) gene polymorphism. Clin Exp Immunol 1995;99:303-10.
Arnalich F, López-Maderuelo D, Codoceo R, Lopez J, Solis-Garrido LM, Capiscol C, et al.
Interleukin-1 receptor antagonist gene polymorphism and mortality in patients with severe sepsis. Clin Exp Immunol 2002;127:331-6.
Li KS, Wang BY, Liu SY, Yao SP, Guo L, Mao DW. The combination of polymorphisms within MCP-1 and IL-1beta associated with ulcerative colitis. Int J Immunogenet 2009;36:135-9.
Dominici R, Cattaneo M, Malferrari G, Archi D, Mariani C, Grimaldi LM, et al.
Cloning and functional analysis of the allelic polymorphism in the transcription regulatory region of interleukin-1 alpha. Immunogenetics 2002;54:82-6.
Wilkinson RJ, Patel P, Llewelyn M, Hirsch CS, Pasvol G, Snounou G, et al.
Influence of polymorphism in the genes for the interleukin (IL)-1 receptor antagonist and IL-1beta on tuberculosis. J Exp Med 1999;189:1863-74.
Hurme M, Santtila S. IL-1 receptor antagonist (IL-1Ra) plasma levels are co-ordinately regulated by both IL-1Ra and IL-1beta genes. Eur J Immunol 1998;28:2598-602.
van den Berg WB, Bresnihan B. Pathogenesis of joint damage in rheumatoid arthritis: Evidence of a dominant role for interleukin-I. Baillieres Best Pract Res Clin Rheumatol 1999;13:577-97.
[Figure 1], [Figure 2]
[Table 1], [Table 2], [Table 3], [Table 4]